Diabetes drug authorised for weight management

The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised a new indication for the diabetes medicine, Mounjaro (tirzepatide), for weight loss and weight management in adults aged 18 and over.

Mounjaro is now authorised for adult patients with a BMI of 30kg/m² or more (obesity), as well as those with a BMI between 27-30kg/m² (overweight) who also have weight-related health problems such as prediabetes, high blood pressure, high cholesterol, or heart problems.

The medicine should be used together with a reduced-calorie diet and increased physical activity.

Tirzepatide, the active ingredient, works by regulating a patient’s appetite so they feel full.

Julian Beach, MHRA Interim Executive Director, Healthcare Quality and Access, said: "We have prioritised rapid assessment of this new indication for Mounjaro, given the public health importance of access to new medicines to help tackle obesity.

"We have drawn on advice from the independent Commission on Human Medicines in coming to our decision, and as with all products, will keep the safety of Mounjaro under close review.


Event Diary

In an age characterised by rapid technological advancements, the Communication Technology Expo stands as a beacon of innovation, education, and connectivity. This annual event has become a pivotal gathering for tech enthusiasts, industry professionals, and curious minds eager to explore the ever-evolving landscape of communication technology. With a commitment to bridging the digital divide and fostering collaboration, the Communication Technology Expo has earned its reputation as a must-attend event in the world of technology.

Origins and Evolution